Cannabinoid Therapeutic Solutions

The European Directorate for the Quality of Medicines & Healthcare (EDQM) has issued a CEP certificate for our Vincamine product, making Linnea the first company in the world to have a CEP-certified Vincamine extract.

Sustainability is a company-wide priority:we partner with local farmers in the Swiss canton of Ticino converting organic waste into energy thanks to a biogas plant, and we voluntarily adhere to the Swiss Private Sector Energy Agency Program, for a minimal CO2 footprint.

Linnea is proud to comply with the new CBD monograph issued by the European Pharmacopoeia. This monograph is applicable for medical prescriptions, pharmacy compounding, clinical trials, pharmaceutical development, and registrations.

LINNEA’S GINKGO BILOBA BOTANICAL EXTRACT IS AN EFFECTIVE ACTIVE INGREDIENT THAT EMBODIES THE COMPANY PHILOSOPHY AND COMMITMENT TO QUALITY WHILE BENEFITING BOTH BODY AND MIND.

BY CLOSELY MONITORING THE ENTIRE PRODUCTION CHAIN, LINNEAENSURES UNIFORMITY AND RELIABILITY ACROSS ALL BATCHES OF ITS REDCLOVER EXTRACT, COMPOSED OF A PRECISE RATIO OF FOUR DIFFERENT ISOFLAVONES (FORMONONETIN, BIOCHAIN A, GENISTEIN AND DAIDZEIN).

OUR HMRLIGNAN™ IS A CONCENTRATED WELLSPRING OF HEALTH, PROVIDING EXPONENTIALLY MORE LIGNANS COMPARED TO DIETARY SOURCES.

A snapshot of Linnea, its mission, vision, commitment to the environment and product sheets of the full Linnea API portfolio.

At LINNEA we use innovative technology to transform natural botanical raw materials into high quality trusted ingredients that will improve people’s lives.

A peripherally-acting antimuscarinic and anticholinergic agent, Linnea hasproduced Butylscopolamine since 1982. This semi-synthetic derivative isobtained from the leaves of the Duboisia plant in Linnea’s plantation in Australia.

Here you can find Linnea Cannabinoids brochure. You can also visit our Cannabinoids webiste at: www.linneacannabinoids.ch